로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > ErbB3

ErbB3

요약

Name:Receptor tyrosine-protein kinase erbB-3
Target Synonym:EC:2.7.10.1,FERLK,EC 2.7.10,Proto-oncogene-like protein c-ErbB-3,HER3,ERBB3,Erb-B2 Receptor Tyrosine Kinase 3,V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 3,Tyrosine Kinase-Type Cell Surface Receptor HER3,Human Epidermal Growth Factor Receptor 3,Lethal Congenital Contracture Syndrome 2,Receptor Tyrosine-Protein Kinase ErbB-3,EC 2.7.10.1,P180-ErbB3,P45-SErbB3,P85-SErbB3,MDA-BF-1,C-ErbB-3,C-ErbB3,ErbB3-S,ErbB-3,LCCS2,Receptor, ErbB-3
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:21
Lastest Research Phase:Approved

제품 리스트 비교 또는 구매

일부의 생물활성 데이터

ER3-H82E6-ELISA
Biotinylated Human ErbB3, His,AvitagBiotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) ELISA bioactivity

Immobilized Biotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human NRG1 Beta 1, Fc Tag (Cat. No. NR1-H5268) with a linear range of 0.2-3 ng/mL (QC tested).

ER3-H82E6-MALS-HPLC
Biotinylated Human ErbB3, His,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) is more than 90% and the molecular weight of this protein is around 78-106 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human ErbB3, His,AvitagBiotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) ELISA bioactivity

Immobilized Biotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human NRG1 Beta 1, Fc Tag (Cat. No. NR1-H5268) with a linear range of 0.2-3 ng/mL (QC tested).

Synonym Name

ERBB3,HER3,LCCS2,MDA-BF-1,MGC88033,c-erbB3,erbB3-S,p180-ErbB3,p45-sErbB3,p85-sErbB3

Background

ErbB3,also known as Her3 (human epidermal growth factor receptor 3), is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound glycoprotein has a neuregulin binding domain but has not an active kinase domain. It therefore can bind the ligand but cannot mediate the intracellular signal transduction through protein phosphorylation. However, it does form heterodimers with ErbB2 or other EGFR members responsible for tyrosine phosphorylation to give a receptor complex and initiate the related pathway, which lead to cell proliferation or differentiation. Overexpression of this protein has been reported in numerous cancers, including prostate, bladder, and breast tumors. This protein has different isoforms derived from alternative splicing variants, and among which, the secreted isoform lacking the intermembrane region modulates the activity of membrane-bound form.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Osimertinib Mesylate AZD-9291 Mesylate; AZD9291; AZD-9291; RDL94R2A16 Approved Astrazeneca Pharmaceutical Co Ltd 泰瑞沙, Tagrisso Mainland China Carcinoma, Non-Small-Cell Lung Astrazeneca Ab 2015-11-13 Lung Diseases; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Brain metastases; Lung Neoplasms; Neoplasms, Nerve Tissue; Meningeal Neoplasms; Respiratory Tract Neoplasms; Solid tumours; Respiratory Tract Diseases; Neoplasms; Glioblastoma; Carcinoma; Bronchial Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Recombinat humanized HER3-targeting antibody Phase 1 Clinical Shanghai Institute Of Biological Products Co Ltd Solid tumours Details
Sirotinib Maleate XZP-5491 Phase 1 Clinical Shandong Xuanzhu Pharmaceutical Technology Co Ltd Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
Patritumab Deruxtecan U3-1402 Phase 2 Clinical Daiichi Sankyo Co Ltd Carcinoma, Non-Small-Cell Lung Details
SIBP-03 SIBP-03 Phase 1 Clinical Shanghai Institute Of Biological Products Co Ltd Neoplasms Details
Duligotuzumab RO-5541078; RG-7597; MEHD-7945A Genentech Inc Details
REGN-1400 REGN-1400 Regeneron Pharmaceuticals Inc Details
Elisidepsin PM-2734; PM-02734 Pharma Mar Sa Details
AC-480 AC-480; BMS-599626 Bristol-Myers Squibb Company Details
Sym-013 Sym-013 Symphogen Details
GSK-2849330 GSK-2849330 Glaxosmithkline Plc Details
Barecetamab ISU-104 Isu Abxis Details
KTN-3379 CDX-3379; KTN-3379 Medimmune Details
JK-07 JK-07 Shenzhen Salubris Pharmaceuticals Co Ltd Details
MM-111 MM-111 Merrimack Details
Tesevatinib XL-647; KD-020; KD-019; EXEL-7647 Exelixis Inc Details
Seribantumab MM-121; SAR-256212; 1N3L70MDFX (UNII code) Merrimack Details
Patritumab AMG-888; U3-1287 Amgen Inc, Daiichi Sankyo Co Ltd Details
AV-203 AV-203; CAN-017 Phase 1 Clinical Aveo Neoplasms Details
Sapitinib AZD-8931 Astrazeneca Pharmaceutical Co Ltd Details
Lumretuzumab RG-7116; RO-5479599 F. Hoffmann-La Roche Ltd Details
MP-0274 DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 Molecular Partners Ag Details
Recombinant Human Neuromodulin 1-Anti-HER3 Antibody Fusion Protein(Salubris) SAL-007 Phase 1 Clinical Shenzhen Salubris Pharmaceuticals Co Ltd Heart Failure Details
Recombinant human ErbB3 fragment vaccine (Zensun) rhErbB3-f Phase 1 Clinical Zensun (Shanghai) Sci&Tech Co Ltd Neoplasms Details
Zenocutuzumab MCLA-128 Phase 2 Clinical Merus Solid tumours; Pancreatic Neoplasms; Breast Neoplasms Details
Allitinib Tosylate AST-6; ALS-1306; AST-1306 Phase 2 Clinical Shanghai Allist Pharmaceutical Technology Co Ltd Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
HMBD-001 HMBD-001 Phase 2 Clinical Hummingbird Bioscience Solid tumours Details
Elgemtumab NOV-6; LJM-716 Phase 1 Clinical Novartis Pharma Ag, Morphosys Ag Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Esophageal Squamous Cell Carcinoma Details
BL-B01D1 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Neoplasms, Fibroepithelial; Solid tumours; Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Urologic Neoplasms; Gastrointestinal Neoplasms Details
Izalontamab SI-B001; SI-1X6.4 Phase 3 Clinical Sichuan Baili Pharmaceutical Co Ltd Head and Neck Neoplasms; Solid tumours; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop